In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Apixaban Study Halted – But It May Not Cause Much Damage To The Program

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

The Phase III APPRAISE-2 trial of Bristol-Myers Squibb/Pfizer’s apixaban in acute coronary syndrome has been terminated due to increased bleeding, on the recommendation of a data safety monitoring committee.
Advertisement

Related Content

Xarelto Back On Track: J&J Answers "Complete Response" Letter And Files For Atrial Fibrillation
Xarelto Back On Track: J&J Answers "Complete Response" Letter And Files For Atrial Fibrillation
Xarelto Back On Track: J&J Answers "Complete Response" Letter And Files For Atrial Fibrillation
Amid Torrent Of Next-Gen Anticoagulant Data, Trial Design Differences Complicate Comparisons Between Potential Competitors
Oral Anticoagulants Market Snapshot: Big Bucks, But Payers Are On Guard

Topics

Advertisement
UsernamePublicRestriction

Register

PS004607

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel